{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:57:39Z","timestamp":1793361459601,"version":"4.5.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.1001\/jamaoncol.2019.5909","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T16:31:27Z","timestamp":1579797087000},"page":"393","source":"Crossref","is-referenced-by-count":46,"title":["Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada"],"prefix":"10.1001","volume":"6","author":[{"given":"Jill","family":"Furzer","sequence":"first","affiliation":[{"name":"Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Nathan","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Schechter","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Pole","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Group of Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Krueger","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Pechlivanoglou","sequence":"additional","affiliation":[{"name":"Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi190105r1","doi-asserted-by":"publisher","first-page":"e945","DOI":"10.1542\/peds.2013-3926","article-title":"Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009.","volume":"134","author":"Siegel","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"coi190105r2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Trends in childhood cancer incidence in the US (1992-2004).","volume":"112","author":"Linabery","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"coi190105r4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group.","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi190105r5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3324\/haematol.2012.068361","article-title":"Improvements in the survival of children and adolescents with acute lymphoblastic leukemia.","volume":"97","author":"Cools","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"coi190105r6","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study.","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"coi190105r7","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia.","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"coi190105r8","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia.","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"issue":"3","key":"coi190105r9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/03007995.2017.1384373","article-title":"Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia.","volume":"34","author":"Crotta","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"coi190105r10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bbmt.2010.03.016","article-title":"The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia.","volume":"16","author":"Lin","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"coi190105r11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/107327481101800407","article-title":"Graft-vs-host disease following allogeneic hematopoietic cell transplantation.","volume":"18","author":"Pidala","year":"2011","journal-title":"Cancer Control"},{"issue":"1","key":"coi190105r12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children.","volume":"57","author":"Baird","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"16","key":"coi190105r14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia.","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"coi190105r15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11864-016-0406-4","article-title":"CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia.","volume":"17","author":"Singh","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"26","key":"coi190105r16","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"5","key":"coi190105r17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"coi190105r18","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475?000 cancer drug.","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"issue":"15","key":"coi190105r19","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMp1807382","article-title":"National coverage analysis of CAR-T therapies: policy, evidence, and payment.","volume":"379","author":"Bach","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"coi190105r20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"immunotherapy: tisagenlecleucel: the first approved CAR-T-cell therapy: implications for payers and policy makers.","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"coi190105r21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia.","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi190105r22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia.","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"4","key":"coi190105r25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0272989X16651869","article-title":"Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial.","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"issue":"1","key":"coi190105r26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/asheducation-2014.1.559","article-title":"Chimeric antigen receptor T-cell therapy for ALL.","volume":"2014","author":"Maude","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"coi190105r27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1524-4733.2007.00180.x","article-title":"The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia.","volume":"10","author":"Costa","year":"2007","journal-title":"Value Health"},{"issue":"5","key":"coi190105r28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pbc.v62.5","article-title":"Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia.","volume":"62","author":"Kelly","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"coi190105r29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/ijc.25433","article-title":"Quality of life during active treatment for pediatric acute lymphoblastic leukemia.","volume":"128","author":"Sung","year":"2011","journal-title":"Int J Cancer"},{"issue":"9967","key":"coi190105r31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"coi190105r33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2015.137","article-title":"Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.","volume":"50","author":"Kurosawa","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"coi190105r34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/bmt.2014.96","article-title":"Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study.","volume":"49","author":"Lawitschka","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"coi190105r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"issue":"2","key":"coi190105r37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"coi190105r38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/pbc.v59.4","article-title":"Health-related quality of life among children with acute lymphoblastic leukemia.","volume":"59","author":"Furlong","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"coi190105r39","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/pbc.v48:4","article-title":"Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada.","volume":"48","author":"MacArthur","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"coi190105r43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"8","key":"coi190105r44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/(ISSN)1099-1050","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves.","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"issue":"2","key":"coi190105r45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/leu.2014.203","article-title":"Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy.","volume":"29","author":"Nelson","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"coi190105r46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"coi190105r49","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40273-019-00799-0","article-title":"Tisagenlecleucel for the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years: an evidence review group perspective of a NICE single technology appraisal.","volume":"37","author":"Walton","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"coi190105r50","article-title":"CAR T-cell therapy: a microcosm for the challenges ahead in Medicare","author":"Jacobson","journal-title":"JAMA"},{"key":"coi190105r3","author":"American Cancer Society"},{"key":"coi190105r23"},{"key":"coi190105r30"},{"key":"coi190105r48","author":"CADTH","year":"2019"},{"key":"coi190105r13","unstructured":"Ontario Ministry of Health and Long Term Care. Health data branch web portal. https:\/\/hsim.health.gov.on.ca\/hdbportal\/. Accessed December 9, 2019."},{"key":"coi190105r24","unstructured":"CADTH. Guidelines for the Economic Evaluation of Health Technologies: Canada\u20144th Edition. March 2017. https:\/\/www.cadth.ca\/dv\/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed December 10, 2019."},{"key":"coi190105r32","unstructured":"Ontario Ministry of Health and Long Term Care. Ontario drug formulary. https:\/\/www.formulary.health.gov.on.ca\/formulary\/. Accessed December 10, 2019."},{"key":"coi190105r35","unstructured":"Canadian Institute for Health Informatics. Cost of a standard hospital stay details for hospital for sick children. https:\/\/yourhealthsystem.cihi.ca\/hsp\/indepth?lang=en#\/indicator\/015\/4\/O5109\/. Accessed December 13, 2019."},{"key":"coi190105r40","unstructured":"Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r\/r B-cell ALL [press release]. Basel, Switzerland: Novartis; June 23, 2017."},{"key":"coi190105r41","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Oncologic drug advisory committee (ODAC) morning session. July 12, 2017. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM573720.pdf. Accessed December 13, 2019."},{"key":"coi190105r42","unstructured":"SzaboL. New gene therapy treatment could hit $1M per patient because of additional costs. USA Today. October 16, 2017. https:\/\/www.usatoday.com\/story\/news\/2017\/10\/16\/new-gene-therapy-treatment\/769240001\/. Accessed December 10, 2019."},{"key":"coi190105r47","unstructured":"GradyD. FDA panel recommends approval for gene-altering leukemia treatment. The New York Times. July 12, 2017. https:\/\/www.nytimes.com\/2017\/07\/12\/health\/fda-novartis-leukemia-gene-medicine.html. Accessed December 10, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2758837\/jamaoncology_furzer_2020_oi_190105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T15:01:12Z","timestamp":1584025272000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2758837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.5909","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}